MK-0752
- Generic Name
- MK-0752
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21ClF2O4S
- CAS Number
- 471905-41-6
- Unique Ingredient Identifier
- 9JD9B4S53T
- Background
Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01295632
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Phase 1
Terminated
- Conditions
- Neoplasms Malignant
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01243762
A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00803894
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 22
- Registration Number
- NCT00756717
- Locations
- 🇺🇸
Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Phase 1
Terminated
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 33
- Registration Number
- NCT00572182
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath